<DOC>
	<DOCNO>NCT01461161</DOCNO>
	<brief_summary>This study determine effect food single dose 20 mg bardoxolone methyl administer normal healthy adult subject .</brief_summary>
	<brief_title>A Single-Dose , Open-Label , Randomized , Food Effect Blinded , Randomized , Dose Proportionality Study Healthy Volunteers With Bardoxolone Methyl</brief_title>
	<detailed_description />
	<criteria>1 . Males Females 18 45 year age ; 2 . Willing practice method birth control ( male partner childbearing potential female childbearing potential ) screening , take study drug least 30 day last dose study drug ingest ; 3 . Female subject childbearing potential must nonpregnant nonlactating negative serum pregnancy test result prior enrollment trial ; 4 . Body mass index ( BMI ) 19 31 kg/m2 ; 5 . Willing able give write informed consent study participation provide consent access medical data accord appropriate local data protection legislation , allow authorization access medical record describe event capture endpoint ; 6 . Willing able cooperate aspect protocol . 1 . Participated another clinical trial investigational drug ( medical device ) within last 30 day , currently participate another trial investigational drug ( medical device ) ; 2 . Any condition possibly affect absorption , distribution , metabolism excretion drug may confound analysis conduct study [ e.g. , previous surgery gastrointestinal tract include removal part stomach , bowel , liver , gall bladder , pancreas ] ; 3 . Known hypersensitivity component formulation study drug , bardoxolone methyl ; 4 . Evidence history concurrent clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose administration ) , hematological , endocrine , immunological , renal , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease judgment investigator could potentially either pose health risk subject study influence study outcome ; 5 . Evidence hepatic biliary dysfunction include elevation total bilirubin , direct bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gamma glutamyl transpeptidase ( GGT ) , lactate dehydrogenase ( LDH ) , alkaline phosphatase level great upper limit normal ( ULN ) ; 6 . Positive test result human immunodeficiency virus type 1 2 antibody , hepatitis B surface antigen , hepatitis C virus antibody screening ; 7 . Any medical dental procedure , matter minor , plan anticipate occur conduct study ; 8 . History drug alcohol abuse dependence within last year ; 9 . Any vaccination within 30 day start study throughout study ; 10 . Use need systemic drug ( ) include vitamin herbal preparation drug use contraception , within 30 day entry study study ; 11 . Use aspirin , nonsteroidal antiinflammatory agent , acetaminophen within 5 day prior ingestion study drug ; use aspirin nonsteroidal anti inflammatory agent ( acetaminophen ) allow isolated episode pain discretion investigator ; 12 . Donation receipt blood blood component within 4 week prior study . The investigator instruct subject participate study donate blood blood component 4 week completion study ; 13 . Any diagnostic intervention procedure require contrast agent within 30 day prior study participation ; 14 . Sustained systolic blood pressure &gt; 140 mmHg &lt; 100 mmHg diastolic blood pressure &gt; 95 mmHg screen baseline measure 5 minute sit position . Blood pressure may retested twice sit position interval 5 minute . The pressure elevation consider sustain either systolic diastolic pressure exceed state limit three assessment ; 15 . A pulse rate rest &lt; 45 bpm &gt; 100 bpm ; 16 . Abnormal screen ECG interpret investigator clinically significant ; 17 . Used tobaccocontaining product ( e.g. , cigarette , cigar , chew tobacco , snuff , etc . ) product smoke cessation 2 week prior Day 1 Period 1 study ; 18 . Consumed alcohol xanthinecontaining product ( e.g. , tea , coffee , chocolate , cola , etc . ) within 72 hour prior Day 1 Period 1 study ; 19 . Treated within 30 day Day 1 Period 1 , 5 halflives twice duration biological effect previous investigational drug ( whichever longer ) investigational agent ; 20 . A positive history drug abuse test positive drug ( ) abuse , ethanol , amphetamine , barbiturate , cocaine , opiates , benzodiazepine , cannabinoids cotinine ( indicate active current smoking ) screening Day 1 Period 1 visit ; 21 . Female subject plan pregnancy pregnant lactating ; 22 . Deemed investigator inappropriate study , include subject unable communicate investigator due language problem , poor mental development , impaired cerebral function ; 23 . Any concurrent clinical condition judgment investigator could either potentially pose health risk subject involve study could potentially influence study outcome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>